Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Jul-03-22 | Apr-03-22 | Jan-02-22 | Oct-03-21 | Jul-04-21 | Apr-04-21 | Jan-03-21 | Sep-27-20 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Pharmaceutical | 53,468.0 | 52,631.0 | 51,863.0 | 49,843.0 | 48,267.0 | 46,539.0 | 45,572.0 | 43,852.0 |
| Medical Devices | | | | | | | 22,959.0 | 23,002.0 |
| Other | 28,617.0 | 28,746.0 | 28,409.0 | 28,370.0 | 28,184.0 | 20,648.0 | 14,053.0 | 14,002.0 |
| Total revenues | 95,588.0 | 94,880.0 | 93,775.0 | 91,446.0 | 89,190.0 | 84,214.0 | 82,584.0 | 80,856.0 |
| Revenue growth [+] | 7.2% | 12.7% | 13.6% | 13.1% | 10.8% | 1.8% | 0.6% | -1.0% |
| Pharmaceutical | 10.8% | 13.1% | 13.8% | 13.7% | 11.4% | 8.0% | 8.0% | 4.8% |
| Medical Devices | | | | | | | -11.6% | -11.5% |
| Cost of goods sold | 30,722.0 | 30,390.0 | 29,855.0 | 29,714.0 | 29,436.0 | 28,428.0 | 28,427.0 | 27,747.0 |
| Gross profit | 64,866.0 | 64,490.0 | 63,920.0 | 61,732.0 | 59,754.0 | 55,786.0 | 54,157.0 | 53,109.0 |
| Gross margin | 67.9% | 68.0% | 68.2% | 67.5% | 67.0% | 66.2% | 65.6% | 65.7% |
| Selling, general and administrative [+] | 25,318.0 | 25,165.0 | 24,659.0 | 23,962.0 | 23,393.0 | 22,313.0 | 22,084.0 | 21,666.0 |
| Sales and marketing | 18,164.0 | 18,011.0 | | 17,505.0 | 16,936.0 | 15,856.0 | | 15,627.0 |
| General and administrative | | | 7,154.0 | | | | 6,457.0 | |
| Research and development | 15,307.0 | 14,998.0 | 14,714.0 | 14,026.0 | 13,444.0 | 12,757.0 | 12,159.0 | 11,359.0 |
| EBITDA [+] | 31,411.0 | 31,592.0 | 31,937.0 | 31,231.0 | 30,408.0 | 28,094.0 | 27,145.0 | 27,191.0 |
| EBITDA growth | 3.3% | 12.5% | 17.7% | 14.9% | 12.0% | -1.4% | -3.0% | -2.1% |
| EBITDA margin | 32.9% | 33.3% | 34.1% | 34.2% | 34.1% | 33.4% | 32.9% | 33.6% |
| Depreciation | 2,670.0 | 2,665.0 | 2,690.0 | 2,587.0 | 2,591.0 | 2,578.0 | 2,531.0 | 2,507.0 |
| EBITA | 28,741.0 | 28,927.0 | 29,247.0 | 28,644.0 | 27,817.0 | 25,516.0 | 24,614.0 | 24,684.0 |
| EBITA margin | 30.1% | 30.5% | 31.2% | 31.3% | 31.2% | 30.3% | 29.8% | 30.5% |
| Amortization of intangibles | 4,500.0 | 4,600.0 | 4,700.0 | 4,900.0 | 4,900.0 | 4,800.0 | 4,700.0 | 4,600.0 |
| EBIT [+] | 24,241.0 | 24,327.0 | 24,547.0 | 23,744.0 | 22,917.0 | 20,716.0 | 19,914.0 | 20,084.0 |
| EBIT growth | 5.8% | 17.4% | 23.3% | 18.2% | 13.8% | -3.6% | -5.0% | -3.7% |
| EBIT margin | 25.4% | 25.6% | 26.2% | 26.0% | 25.7% | 24.6% | 24.1% | 24.8% |
| Non-recurring items [+] | 1,808.0 | 1,779.0 | 1,152.0 | 1,166.0 | 412.0 | 423.0 | 428.0 | 435.0 |
| In-process research & development | | 1,510.0 | | 937.0 | | | 181.0 | 144.0 |
| Interest expense, net [+] | 16.0 | 70.0 | 130.0 | 157.0 | 182.0 | 180.0 | 90.0 | 20.0 |
| Interest expense | 128.0 | 130.0 | 183.0 | 210.0 | 234.0 | 239.0 | 201.0 | 199.0 |
| Interest income | 112.0 | 60.0 | 53.0 | 53.0 | 52.0 | 59.0 | 111.0 | 179.0 |
| Other income (expense), net | -2,030.0 | -1,269.0 | -489.0 | -2,834.0 | -2,184.0 | -2,696.0 | -2,899.0 | -561.0 |
| Pre-tax income | 20,387.0 | 21,209.0 | 22,776.0 | 19,587.0 | 20,139.0 | 17,417.0 | 16,497.0 | 19,068.0 |
| Income taxes | 2,021.0 | 1,379.0 | 1,898.0 | 1,707.0 | 2,372.0 | 2,302.0 | 1,783.0 | 2,082.0 |
| Tax rate | 9.9% | 6.5% | 8.3% | 8.7% | 11.8% | 13.2% | | 10.9% |
| Net income | 18,366.0 | 19,830.0 | 20,878.0 | 17,880.0 | 17,767.0 | 15,115.0 | 14,714.0 | 16,986.0 |
| Net margin | 19.2% | 20.9% | 22.3% | 19.6% | 19.9% | 17.9% | 17.8% | 21.0% |
| |
| Basic EPS [+] | $6.98 | $7.54 | $7.93 | $6.79 | $6.75 | $5.74 | $5.59 | $6.44 |
| Growth | 3.4% | 31.2% | 41.9% | 5.4% | 17.2% | -11.6% | -2.1% | 21.0% |
| Diluted EPS [+] | $6.88 | $7.42 | $7.81 | $6.69 | $6.65 | $5.66 | $5.51 | $6.36 |
| Growth | 3.4% | 31.1% | 41.7% | 5.3% | 17.1% | -11.6% | -2.1% | 21.1% |
| |
| Dividends per share [+] | $4.31 | $4.24 | $4.19 | $4.14 | $4.09 | $4.04 | $3.98 | $3.92 |
| Growth | 5.4% | 5.0% | 5.3% | 5.7% | 6.1% | 6.4% | 6.3% | 5.9% |
| |
| Shares outstanding (basic) [+] | 2,630.9 | 2,631.6 | 2,632.2 | 2,632.4 | 2,632.4 | 2,632.5 | 2,633.0 | 2,636.1 |
| Growth | -0.1% | 0.0% | 0.0% | -0.1% | -0.2% | -0.3% | -0.6% | -0.8% |
| Shares outstanding (diluted) [+] | 2,670.8 | 2,671.8 | 2,673.3 | 2,672.5 | 2,671.1 | 2,669.6 | 2,669.1 | 2,672.5 |
| Growth | 0.0% | 0.1% | 0.2% | 0.0% | -0.1% | -0.4% | -0.6% | -0.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|